nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Doxacurium chloride—BCHE—breast cancer	0.00932	0.515	CrCbGaD
Cisatracurium Besylate—Mivacurium—BCHE—breast cancer	0.00877	0.485	CrCbGaD
Cisatracurium Besylate—Erythema—Thiotepa—breast cancer	0.00219	0.00223	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Goserelin—breast cancer	0.00217	0.00221	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Melphalan—breast cancer	0.00214	0.00218	CcSEcCtD
Cisatracurium Besylate—Rash—Ixabepilone—breast cancer	0.00214	0.00218	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Ixabepilone—breast cancer	0.00214	0.00218	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Irinotecan—breast cancer	0.00214	0.00218	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—breast cancer	0.00213	0.00217	CcSEcCtD
Cisatracurium Besylate—Angioedema—Vinorelbine—breast cancer	0.0021	0.00214	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Melphalan—breast cancer	0.00209	0.00213	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Goserelin—breast cancer	0.00209	0.00213	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Melphalan—breast cancer	0.00208	0.00212	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Gemcitabine—breast cancer	0.00208	0.00212	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Goserelin—breast cancer	0.00205	0.00209	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Goserelin—breast cancer	0.00204	0.00208	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Goserelin—breast cancer	0.00203	0.00207	CcSEcCtD
Cisatracurium Besylate—Flushing—Irinotecan—breast cancer	0.00202	0.00206	CcSEcCtD
Cisatracurium Besylate—Rash—Anastrozole—breast cancer	0.00202	0.00206	CcSEcCtD
Cisatracurium Besylate—Rash—Letrozole—breast cancer	0.00202	0.00206	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Letrozole—breast cancer	0.00202	0.00205	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Anastrozole—breast cancer	0.00202	0.00205	CcSEcCtD
Cisatracurium Besylate—Hypotension—Melphalan—breast cancer	0.002	0.00204	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Capecitabine—breast cancer	0.002	0.00204	CcSEcCtD
Cisatracurium Besylate—Hypertension—Vinorelbine—breast cancer	0.00198	0.00202	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Irinotecan—breast cancer	0.00197	0.00201	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Irinotecan—breast cancer	0.00196	0.002	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Irinotecan—breast cancer	0.00196	0.002	CcSEcCtD
Cisatracurium Besylate—Hypotension—Goserelin—breast cancer	0.00196	0.00199	CcSEcCtD
Cisatracurium Besylate—Urticaria—Chlorambucil—breast cancer	0.00195	0.00199	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Tamoxifen—breast cancer	0.00195	0.00199	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—breast cancer	0.00194	0.00198	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Gemcitabine—breast cancer	0.00192	0.00196	CcSEcCtD
Cisatracurium Besylate—Rash—Raloxifene—breast cancer	0.00192	0.00195	CcSEcCtD
Cisatracurium Besylate—Rash—Idarubicin—breast cancer	0.00192	0.00195	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Gemcitabine—breast cancer	0.00191	0.00195	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Idarubicin—breast cancer	0.00191	0.00195	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Raloxifene—breast cancer	0.00191	0.00195	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Melphalan—breast cancer	0.00191	0.00195	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Gemcitabine—breast cancer	0.00191	0.00194	CcSEcCtD
Cisatracurium Besylate—Convulsion—Thiotepa—breast cancer	0.0019	0.00193	CcSEcCtD
Cisatracurium Besylate—Erythema—Mitoxantrone—breast cancer	0.00189	0.00193	CcSEcCtD
Cisatracurium Besylate—Hypertension—Thiotepa—breast cancer	0.00189	0.00193	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Vinorelbine—breast cancer	0.00187	0.00191	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Goserelin—breast cancer	0.00187	0.0019	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Capecitabine—breast cancer	0.00186	0.00189	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—breast cancer	0.00185	0.00189	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Docetaxel—breast cancer	0.00185	0.00188	CcSEcCtD
Cisatracurium Besylate—Erythema—Gemcitabine—breast cancer	0.00184	0.00188	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Vinorelbine—breast cancer	0.00184	0.00187	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Vinorelbine—breast cancer	0.00183	0.00186	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Vinorelbine—breast cancer	0.00182	0.00185	CcSEcCtD
Cisatracurium Besylate—Erythema—Fluorouracil—breast cancer	0.00181	0.00185	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Chlorambucil—breast cancer	0.00181	0.00185	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Paclitaxel—breast cancer	0.00181	0.00184	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Capecitabine—breast cancer	0.00179	0.00182	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Thiotepa—breast cancer	0.00176	0.00179	CcSEcCtD
Cisatracurium Besylate—Hypotension—Vinorelbine—breast cancer	0.00175	0.00178	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Thiotepa—breast cancer	0.00175	0.00178	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Paclitaxel—breast cancer	0.00174	0.00178	CcSEcCtD
Cisatracurium Besylate—Pruritus—Chlorambucil—breast cancer	0.00174	0.00177	CcSEcCtD
Cisatracurium Besylate—Urticaria—Tamoxifen—breast cancer	0.00174	0.00177	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Thiotepa—breast cancer	0.00174	0.00177	CcSEcCtD
Cisatracurium Besylate—Urticaria—Melphalan—breast cancer	0.0017	0.00174	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Vinorelbine—breast cancer	0.00167	0.0017	CcSEcCtD
Cisatracurium Besylate—Urticaria—Goserelin—breast cancer	0.00166	0.00169	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vinblastine—breast cancer	0.00166	0.00169	CcSEcCtD
Cisatracurium Besylate—Flushing—Paclitaxel—breast cancer	0.00165	0.00168	CcSEcCtD
Cisatracurium Besylate—Convulsion—Mitoxantrone—breast cancer	0.00164	0.00167	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mitoxantrone—breast cancer	0.00163	0.00167	CcSEcCtD
Cisatracurium Besylate—Hypertension—Irinotecan—breast cancer	0.00163	0.00167	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—breast cancer	0.00162	0.00165	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Tamoxifen—breast cancer	0.00161	0.00164	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Paclitaxel—breast cancer	0.00161	0.00164	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Paclitaxel—breast cancer	0.0016	0.00163	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Paclitaxel—breast cancer	0.0016	0.00163	CcSEcCtD
Cisatracurium Besylate—Hypertension—Gemcitabine—breast cancer	0.00159	0.00162	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Melphalan—breast cancer	0.00158	0.00161	CcSEcCtD
Cisatracurium Besylate—Convulsion—Fluorouracil—breast cancer	0.00157	0.0016	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	0.00156	0.00159	CcSEcCtD
Cisatracurium Besylate—Pruritus—Tamoxifen—breast cancer	0.00155	0.00158	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Mitoxantrone—breast cancer	0.00155	0.00157	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Irinotecan—breast cancer	0.00155	0.00157	CcSEcCtD
Cisatracurium Besylate—Erythema—Paclitaxel—breast cancer	0.00154	0.00157	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Goserelin—breast cancer	0.00154	0.00157	CcSEcCtD
Cisatracurium Besylate—Pruritus—Melphalan—breast cancer	0.00152	0.00155	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Irinotecan—breast cancer	0.00152	0.00154	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Epirubicin—breast cancer	0.00151	0.00154	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Mitoxantrone—breast cancer	0.00151	0.00154	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Gemcitabine—breast cancer	0.00151	0.00153	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mitoxantrone—breast cancer	0.0015	0.00153	CcSEcCtD
Cisatracurium Besylate—Urticaria—Vinorelbine—breast cancer	0.00149	0.00152	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Capecitabine—breast cancer	0.00148	0.00151	CcSEcCtD
Cisatracurium Besylate—Pruritus—Goserelin—breast cancer	0.00148	0.00151	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Fluorouracil—breast cancer	0.00148	0.00151	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Docetaxel—breast cancer	0.00148	0.0015	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Gemcitabine—breast cancer	0.00148	0.0015	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Gemcitabine—breast cancer	0.00146	0.00149	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Fluorouracil—breast cancer	0.00145	0.00148	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Fluorouracil—breast cancer	0.00144	0.00147	CcSEcCtD
Cisatracurium Besylate—Hypotension—Mitoxantrone—breast cancer	0.00144	0.00147	CcSEcCtD
Cisatracurium Besylate—Hypotension—Irinotecan—breast cancer	0.00144	0.00147	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Capecitabine—breast cancer	0.00143	0.00146	CcSEcCtD
Cisatracurium Besylate—Urticaria—Thiotepa—breast cancer	0.00142	0.00145	CcSEcCtD
Cisatracurium Besylate—Angioedema—Paclitaxel—breast cancer	0.00141	0.00144	CcSEcCtD
Cisatracurium Besylate—Hypotension—Gemcitabine—breast cancer	0.00141	0.00143	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—breast cancer	0.0014	0.00143	CcSEcCtD
Cisatracurium Besylate—Flushing—Docetaxel—breast cancer	0.0014	0.00142	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Epirubicin—breast cancer	0.00139	0.00142	CcSEcCtD
Cisatracurium Besylate—Hypotension—Fluorouracil—breast cancer	0.00138	0.00141	CcSEcCtD
Cisatracurium Besylate—Rash—Tamoxifen—breast cancer	0.00138	0.00141	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vinorelbine—breast cancer	0.00138	0.00141	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Tamoxifen—breast cancer	0.00138	0.00141	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mitoxantrone—breast cancer	0.00138	0.0014	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Irinotecan—breast cancer	0.00138	0.0014	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Docetaxel—breast cancer	0.00136	0.00139	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Docetaxel—breast cancer	0.00136	0.00138	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Docetaxel—breast cancer	0.00136	0.00138	CcSEcCtD
Cisatracurium Besylate—Rash—Melphalan—breast cancer	0.00135	0.00138	CcSEcCtD
Cisatracurium Besylate—Flushing—Capecitabine—breast cancer	0.00135	0.00138	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Melphalan—breast cancer	0.00135	0.00138	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Gemcitabine—breast cancer	0.00134	0.00137	CcSEcCtD
Cisatracurium Besylate—Convulsion—Paclitaxel—breast cancer	0.00134	0.00136	CcSEcCtD
Cisatracurium Besylate—Hypertension—Paclitaxel—breast cancer	0.00133	0.00136	CcSEcCtD
Cisatracurium Besylate—Pruritus—Vinorelbine—breast cancer	0.00133	0.00135	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Capecitabine—breast cancer	0.00132	0.00135	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Fluorouracil—breast cancer	0.00132	0.00134	CcSEcCtD
Cisatracurium Besylate—Rash—Goserelin—breast cancer	0.00132	0.00134	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Thiotepa—breast cancer	0.00132	0.00134	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Goserelin—breast cancer	0.00132	0.00134	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Capecitabine—breast cancer	0.00132	0.00134	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Capecitabine—breast cancer	0.00131	0.00134	CcSEcCtD
Cisatracurium Besylate—Erythema—Docetaxel—breast cancer	0.00131	0.00133	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.00131	0.00133	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Epirubicin—breast cancer	0.00129	0.00132	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—breast cancer	0.00129	0.00131	CcSEcCtD
Cisatracurium Besylate—Erythema—Capecitabine—breast cancer	0.00127	0.00129	CcSEcCtD
Cisatracurium Besylate—Pruritus—Thiotepa—breast cancer	0.00127	0.00129	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Paclitaxel—breast cancer	0.00126	0.00128	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Paclitaxel—breast cancer	0.00124	0.00126	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Paclitaxel—breast cancer	0.00123	0.00125	CcSEcCtD
Cisatracurium Besylate—Urticaria—Mitoxantrone—breast cancer	0.00123	0.00125	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Paclitaxel—breast cancer	0.00122	0.00125	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—breast cancer	0.0012	0.00122	CcSEcCtD
Cisatracurium Besylate—Rash—Vinorelbine—breast cancer	0.00118	0.0012	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Vinorelbine—breast cancer	0.00118	0.0012	CcSEcCtD
Cisatracurium Besylate—Hypotension—Paclitaxel—breast cancer	0.00118	0.0012	CcSEcCtD
Cisatracurium Besylate—Urticaria—Fluorouracil—breast cancer	0.00118	0.0012	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Mitoxantrone—breast cancer	0.00114	0.00116	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Irinotecan—breast cancer	0.00114	0.00116	CcSEcCtD
Cisatracurium Besylate—Convulsion—Docetaxel—breast cancer	0.00113	0.00116	CcSEcCtD
Cisatracurium Besylate—Hypertension—Docetaxel—breast cancer	0.00113	0.00115	CcSEcCtD
Cisatracurium Besylate—Rash—Thiotepa—breast cancer	0.00113	0.00115	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Thiotepa—breast cancer	0.00113	0.00115	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Paclitaxel—breast cancer	0.00112	0.00114	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.00111	0.00113	CcSEcCtD
Cisatracurium Besylate—Hypertension—Capecitabine—breast cancer	0.00109	0.00111	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Fluorouracil—breast cancer	0.00109	0.00111	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.00107	0.00109	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Docetaxel—breast cancer	0.00107	0.00109	CcSEcCtD
Cisatracurium Besylate—Pruritus—Gemcitabine—breast cancer	0.00107	0.00108	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Docetaxel—breast cancer	0.00105	0.00107	CcSEcCtD
Cisatracurium Besylate—Pruritus—Fluorouracil—breast cancer	0.00105	0.00107	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Docetaxel—breast cancer	0.00104	0.00106	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Docetaxel—breast cancer	0.00104	0.00106	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Epirubicin—breast cancer	0.00103	0.00105	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Capecitabine—breast cancer	0.00101	0.00103	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Capecitabine—breast cancer	0.00101	0.00103	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Capecitabine—breast cancer	0.001	0.00102	CcSEcCtD
Cisatracurium Besylate—Urticaria—Paclitaxel—breast cancer	0.001	0.00102	CcSEcCtD
Cisatracurium Besylate—Hypotension—Docetaxel—breast cancer	0.000998	0.00102	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Epirubicin—breast cancer	0.000997	0.00102	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—breast cancer	0.000983	0.001	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—breast cancer	0.000979	0.000997	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—breast cancer	0.000977	0.000995	CcSEcCtD
Cisatracurium Besylate—Rash—Mitoxantrone—breast cancer	0.000974	0.000992	CcSEcCtD
Cisatracurium Besylate—Rash—Irinotecan—breast cancer	0.000974	0.000992	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Irinotecan—breast cancer	0.000974	0.000991	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mitoxantrone—breast cancer	0.000974	0.000991	CcSEcCtD
Cisatracurium Besylate—Hypotension—Capecitabine—breast cancer	0.000967	0.000984	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Doxorubicin—breast cancer	0.000955	0.000973	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Docetaxel—breast cancer	0.000952	0.00097	CcSEcCtD
Cisatracurium Besylate—Rash—Gemcitabine—breast cancer	0.000949	0.000967	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Gemcitabine—breast cancer	0.000948	0.000966	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—breast cancer	0.000943	0.000961	CcSEcCtD
Cisatracurium Besylate—Flushing—Epirubicin—breast cancer	0.000941	0.000959	CcSEcCtD
Cisatracurium Besylate—Rash—Fluorouracil—breast cancer	0.000933	0.00095	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Fluorouracil—breast cancer	0.000932	0.00095	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Paclitaxel—breast cancer	0.000929	0.000946	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—breast cancer	0.000922	0.000939	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Capecitabine—breast cancer	0.000922	0.000939	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Epirubicin—breast cancer	0.00092	0.000937	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Epirubicin—breast cancer	0.000916	0.000933	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Epirubicin—breast cancer	0.000914	0.000931	CcSEcCtD
Cisatracurium Besylate—Pruritus—Paclitaxel—breast cancer	0.000892	0.000908	CcSEcCtD
Cisatracurium Besylate—Erythema—Epirubicin—breast cancer	0.000883	0.000899	CcSEcCtD
Cisatracurium Besylate—Flushing—Doxorubicin—breast cancer	0.000871	0.000887	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Doxorubicin—breast cancer	0.000851	0.000867	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—breast cancer	0.000848	0.000863	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—breast cancer	0.000846	0.000861	CcSEcCtD
Cisatracurium Besylate—Urticaria—Capecitabine—breast cancer	0.000822	0.000837	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—breast cancer	0.000817	0.000833	CcSEcCtD
Cisatracurium Besylate—Erythema—Doxorubicin—breast cancer	0.000817	0.000832	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000798	0.000812	CcSEcCtD
Cisatracurium Besylate—Rash—Paclitaxel—breast cancer	0.000795	0.000809	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Paclitaxel—breast cancer	0.000794	0.000809	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Docetaxel—breast cancer	0.000787	0.000802	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—breast cancer	0.00077	0.000784	CcSEcCtD
Cisatracurium Besylate—Convulsion—Epirubicin—breast cancer	0.000765	0.000779	CcSEcCtD
Cisatracurium Besylate—Hypertension—Epirubicin—breast cancer	0.000762	0.000776	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Capecitabine—breast cancer	0.000762	0.000776	CcSEcCtD
Cisatracurium Besylate—Pruritus—Docetaxel—breast cancer	0.000756	0.00077	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—breast cancer	0.000755	0.000769	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—breast cancer	0.000748	0.000762	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000747	0.00076	CcSEcCtD
Cisatracurium Besylate—Pruritus—Capecitabine—breast cancer	0.000732	0.000745	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Epirubicin—breast cancer	0.000721	0.000734	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—breast cancer	0.00072	0.000733	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—breast cancer	0.000708	0.000721	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Epirubicin—breast cancer	0.000707	0.00072	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—breast cancer	0.000705	0.000718	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Epirubicin—breast cancer	0.000703	0.000716	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Epirubicin—breast cancer	0.0007	0.000713	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000691	0.000703	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—breast cancer	0.000686	0.000699	CcSEcCtD
Cisatracurium Besylate—Rash—Docetaxel—breast cancer	0.000674	0.000686	CcSEcCtD
Cisatracurium Besylate—Hypotension—Epirubicin—breast cancer	0.000673	0.000686	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Docetaxel—breast cancer	0.000673	0.000685	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—breast cancer	0.000667	0.000679	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—breast cancer	0.000654	0.000666	CcSEcCtD
Cisatracurium Besylate—Rash—Capecitabine—breast cancer	0.000652	0.000664	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Capecitabine—breast cancer	0.000652	0.000664	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—breast cancer	0.000651	0.000663	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—breast cancer	0.000648	0.00066	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Epirubicin—breast cancer	0.000642	0.000654	CcSEcCtD
Cisatracurium Besylate—Hypotension—Doxorubicin—breast cancer	0.000623	0.000635	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—breast cancer	0.000612	0.000623	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—breast cancer	0.000594	0.000605	CcSEcCtD
Cisatracurium Besylate—Urticaria—Epirubicin—breast cancer	0.000572	0.000583	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—breast cancer	0.000567	0.000578	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—breast cancer	0.000545	0.000555	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Epirubicin—breast cancer	0.000531	0.000541	CcSEcCtD
Cisatracurium Besylate—Urticaria—Doxorubicin—breast cancer	0.00053	0.000539	CcSEcCtD
Cisatracurium Besylate—Pruritus—Epirubicin—breast cancer	0.00051	0.000519	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—breast cancer	0.000491	0.0005	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—breast cancer	0.000486	0.000494	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—breast cancer	0.000485	0.000494	CcSEcCtD
Cisatracurium Besylate—Pruritus—Doxorubicin—breast cancer	0.000472	0.00048	CcSEcCtD
Cisatracurium Besylate—Rash—Epirubicin—breast cancer	0.000454	0.000463	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Epirubicin—breast cancer	0.000454	0.000462	CcSEcCtD
Cisatracurium Besylate—Rash—Doxorubicin—breast cancer	0.00042	0.000428	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—breast cancer	0.00042	0.000428	CcSEcCtD
